Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children:: 6 years of follow-up

被引:64
作者
Resino, S
Resino, R
Micheloud, D
Gutiérrez, DG
Léon, JA
Ramos, JT
Ciria, L
de José, I
Mellado, J
Muñoz-Fernández, A
机构
[1] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Madrid 28007, Spain
[2] Hosp Gen Univ Gregorio Maranon, Lab Inmunopediat, Madrid 28007, Spain
[3] Hosp Univ 12 Octubre, Lab Inmunopediat, Madrid, Spain
[4] Hosp Univ Nino Jesus, Lab Pediat Infecciosas, Madrid, Spain
[5] Hosp Univ La Paz, Lab Inmunopediat, Madrid, Spain
[6] Hosp Univ Carlos III, Lab Pediat Infecciosas, Madrid, Spain
[7] Hosp Univ Virgen Rocio, Lab Pediat Infecciosas, Seville, Spain
关键词
D O I
10.1086/500412
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Several studies of children with human immunodeficiency virus (HIV) type 1 infection have demonstrated sustained increases in CD4(+) cell count, even when virological failure has occurred after receipt of highly active antiretroviral therapy (HAART), but these studies were of limited duration. Moreover, the CD4(+) cell count threshold at which antiretroviral treatment should be initiated is still unsettled. The aim of this study was to define the long-term impact of HAART on CD4(+) cell percentage and viral load according to CD4(+) cell percentages before HAART was initiated. Methods. We conducted a retrospective study of 113 pretreated HIV-1-infected children stratified by pre-HAART CD4(+) cell percentage (< 5%, 5%-15%, 15%-25%, and > 25%). The inclusion criteria were as follows: initiating HAART with a protease inhibitor, having 6 years of follow-up after starting HAART, having a CD4(+) cell count or viral load recorded before initiation of HAART, and having received mono- or dual-nucleoside therapy before starting HAART. Results. During the first 2 years of HAART, HIV-1-infected children experienced a significant increase in CD4(+) cell percentage and a decrease in viral load (P <.05). During their last 4 years of receiving HAART, we found a significant decrease in viral load but not an increase in CD4(+) cell percentage, because the CD4(+) cell percentage reached a plateau after the second year of HAART. Moreover, children with CD4(+) cell percentages of < 5% at baseline did not achieve CD4(+) cell percentages of > 25% after 6 years of HAART. Children with CD4(+) cell percentages of 5%-25% at baseline had a strong negative association with achieving CD4(+) cell percentages of > 30% for at least 6 and 12 months but not with achieving CD4(+) cell percentages of > 30% for at least 24 months. Conclusions. Long-term HAART allowed for restoration of CD4(+) cell counts and control of viral loads in HIV-1-infected children. However, initiating HAART after severe immunosuppression has occurred is detrimental for the restoration of the CD4(+) cell count.
引用
收藏
页码:862 / 869
页数:8
相关论文
共 37 条
[1]   Lipodystrophy syndrome in human immunodeficiency virus-infected children [J].
Amaya, RA ;
Kozinetz, CA ;
McMeans, A ;
Schwarzwald, H ;
Kline, MW .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (05) :405-410
[2]  
American Academy of Pediatrics. Committee on Nutrition, 1998, Pediatrics, V101, P141
[3]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[4]  
[Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1
[5]   Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children [J].
Beregszaszi, M ;
Dollfus, C ;
Levine, M ;
Faye, A ;
Deghmoun, S ;
Bellal, N ;
Houang, M ;
Chevenne, D ;
Hankard, R ;
Bresson, JL ;
Blanche, SP ;
Levy-Marchal, C .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 40 (02) :161-168
[6]   Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy [J].
Chiappini, E ;
Galli, L ;
Zazzi, M ;
de Martino, M .
JOURNAL OF MEDICAL VIROLOGY, 2003, 70 (04) :506-512
[7]   Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia [J].
Deeks, SG ;
Barbour, JD ;
Grant, RM ;
Martin, JN .
AIDS, 2002, 16 (02) :201-207
[8]  
Dunn DT, 2003, LANCET, V362, P1605, DOI 10.1016/S0140-6736(03)14793-9
[9]   Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy [J].
Fraaij, PLA ;
Verweel, G ;
van Rossum, AMC ;
van Lochem, EG ;
Schutten, M ;
Weemaes, CMR ;
Hartwig, NG ;
Burger, DM ;
de Groot, R .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (04) :604-608
[10]  
Gougeon ML, 1996, J IMMUNOL, V156, P3509